Inclusion Criteria:

          1. Age ≥18 years at the time of informed consent.

          2. Morphologically documented primary AML or secondary AML [from prior conditions such as
             Myelodysplastic Syndrome (MDS), myeloproliferative neoplasm (MPN)] or therapy related
             AML (t-AML), as defined by World Health Organization (WHO) criteria.

          3. In first or subsequent relapse or refractory status after prior therapy, with or
             without prior hematopoietic stem cell transplant (HSCT). Patients with MDS and
             progression to AML on hypomethylating agents will also be included.

          4. Eastern Cooperative Oncology Group (ECOG) performance score 0-2.

          5. Greater than 25% of blasts must be CD33 positive on flow cytometry using Phycoerythrin
             (PE) labeled anti-CD33 antibody.

          6. Patients must meet the following clinical laboratory criteria:

               -  Total bilirubin ≤ 2 x the upper limit of the normal range (ULN)

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.

               -  Calculated creatinine clearance ≥ 50 mL/min

               -  Resting left ventricular ejection fraction (LVEF) > 40%

          7. Female patients must agree to avoid becoming pregnant, and male patients should avoid
             impregnating a female partner.

        Exclusion Criteria:

          1. Acute Promyelocytic Leukemia.

          2. Active severe infection not well controlled by antibacterial or antiviral therapy.

          3. Known infection with human immunodeficiency virus.

          4. Patients with documented pulmonary disease, with a diffusing capacity of the lungs for
             carbon monoxide (DLCO) and/or forced expiratory volume in one second (FEV1) <65%, or
             history of dyspnea at rest, or requiring oxygen.

          5. Pregnant or breast feeding women.

          6. Prior chemotherapy or radiotherapy within 14 days of study entry unless fully
             recovered from adverse effects due to treatment, at investigator's discretion.

          7. Active malignancy within 2 years of entry, except previously treated melanoma grade 2
             or less, non-melanoma skin cancer, carcinoma in situ, or cervical intraepithelial
             neoplasia, and organ confined prostate cancer with no evidence of progressive disease
             based on prostate-specific antigen (PSA) levels and are not on active therapy. Active
             malignancy is malignancy receiving treatment.